Massion PP - Search Results

1

ROS1 rearrangements define a unique molecular class of lung cancers.

Bergethon K, Shaw AT, Ou SH, Katayama R, Lovly CM, McDonald NT, Massion PP, Siwak-Tapp C, Gonzalez A, Fang R, Mark EJ, Batten JM, Chen H, Wilner KD, Kwak EL, Clark JW, Carbone DP, Ji H, Engelman JA, Mino-Kenudson M, Pao W, Iafrate AJ. Bergethon K, et al. Among authors: massion pp. J Clin Oncol. 2012 Mar 10;30(8):863-70. doi: 10.1200/JCO.2011.35.6345. Epub 2012 Jan 3. J Clin Oncol. 2012. PMID: 22215748 Free PMC article.

2

From clinical and pathologic to molecular staging of lung cancer.

Massion PP, Carbone DP. Massion PP, et al. Am J Respir Crit Care Med. 2003 Jun 15;167(12):1587-8. doi: 10.1164/rccm.2303006. Am J Respir Crit Care Med. 2003. PMID: 12796051 Review. No abstract available.

3

Proteomic patterns of tumour subsets in non-small-cell lung cancer.

Yanagisawa K, Shyr Y, Xu BJ, Massion PP, Larsen PH, White BC, Roberts JR, Edgerton M, Gonzalez A, Nadaf S, Moore JH, Caprioli RM, Carbone DP. Yanagisawa K, et al. Among authors: massion pp. Lancet. 2003 Aug 9;362(9382):433-9. doi: 10.1016/S0140-6736(03)14068-8. Lancet. 2003. PMID: 12927430

4

Significance of p63 amplification and overexpression in lung cancer development and prognosis.

Massion PP, Taflan PM, Jamshedur Rahman SM, Yildiz P, Shyr Y, Edgerton ME, Westfall MD, Roberts JR, Pietenpol JA, Carbone DP, Gonzalez AL. Massion PP, et al. Cancer Res. 2003 Nov 1;63(21):7113-21. Cancer Res. 2003. PMID: 14612504

5

The molecular basis of lung cancer: molecular abnormalities and therapeutic implications.

Massion PP, Carbone DP. Massion PP, et al. Respir Res. 2003;4(1):12. doi: 10.1186/1465-9921-4-12. Epub 2003 Oct 7. Respir Res. 2003. PMID: 14641911 Free PMC article. Review.

6

Role of p63 amplification and overexpression in lung cancer development.

Massion PP, Taflan PM, Rahman SM, Yildiz P, Shyr Y, Carbone DP, Gonzalez AL. Massion PP, et al. Chest. 2004 May;125(5 Suppl):102S. Chest. 2004. PMID: 15136437 No abstract available.

7

15-Lipoxygenase-2 expression in benign and neoplastic lung: an immunohistochemical study and correlation with tumor grade and proliferation.

Gonzalez AL, Roberts RL, Massion PP, Olson SJ, Shyr Y, Shappell SB. Gonzalez AL, et al. Among authors: massion pp. Hum Pathol. 2004 Jul;35(7):840-9. doi: 10.1016/j.humpath.2004.04.001. Hum Pathol. 2004. PMID: 15257547

8

Nuclear survivin as a biomarker for non-small-cell lung cancer.

Lu B, Gonzalez A, Massion PP, Shyr Y, Shaktour B, Carbone DP, Hallahan DE. Lu B, et al. Among authors: massion pp. Br J Cancer. 2004 Aug 2;91(3):537-40. doi: 10.1038/sj.bjc.6602027. Br J Cancer. 2004. PMID: 15266313 Free PMC article.

9

Aberrant epidermal growth factor receptor signaling and enhanced sensitivity to EGFR inhibitors in lung cancer.

Amann J, Kalyankrishna S, Massion PP, Ohm JE, Girard L, Shigematsu H, Peyton M, Juroske D, Huang Y, Stuart Salmon J, Kim YH, Pollack JR, Yanagisawa K, Gazdar A, Minna JD, Kurie JM, Carbone DP. Amann J, et al. Among authors: massion pp. Cancer Res. 2005 Jan 1;65(1):226-35. Cancer Res. 2005. PMID: 15665299

10

Nuclear survivin predicts recurrence and poor survival in patients with resected nonsmall cell lung carcinoma.

Shinohara ET, Gonzalez A, Massion PP, Chen H, Li M, Freyer AS, Olson SJ, Andersen JJ, Shyr Y, Carbone DP, Johnson DH, Hallahan DE, Lu B. Shinohara ET, et al. Among authors: massion pp. Cancer. 2005 Apr 15;103(8):1685-92. doi: 10.1002/cncr.20951. Cancer. 2005. PMID: 15742356 Free article.

Save citations to file

Email citations

Send citations to clipboard

Add to Collections

Add to My Bibliography

Create a file for external citation management software

Your saved search

Your RSS Feed

My Custom Filters

Publication date

Text availability

Article attribute

Article type

Article Language

Species

Sex

Age

Other

228 results

Search Page

Filters